Finzati - Logo
ALVO logo

Alvotech

ALVO • Drug Manufacturers - Specialty & Generic
$5.32
▼ -0.06 (-1.12%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.90B
Growth
58.8%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 15.6%Healthy liquidity · 1.89Expensive earnings multiple · 51.3
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 21, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$5.32
Change-1.12%
Shares Out356.82M
Market Cap$1.90B
Enterprise Value$3.07B
52W Range2.94 - 9.25
Beta0.18
P/E-10.57
P/S3.86
P/B-9.91
P/FCF-6.28
EV/Sales6.25

Investment DNA

How strong this company looks for long-term investors

59
out of 100
Business Quality
Margins, moat, returns
58/100
Financial Strength
Debt, cash, stability
63/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
64/100
Why this score▼
Positive revenue growth · 15.6%Healthy liquidity · 1.89Expensive earnings multiple · 51.3

Analyst view

Analyst sentiment and price target

ALVO
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
60/100
Neutral
Bullish
2
Hold
2
Bearish
1
Price Target
2026-08-21
Low
$5.00
Mean
$8.60
Median
$10.00
High
$10.00

Company Overview

IPO: 6/16/2022
Industry: Drug Manufacturers - Specialty & Generic
P/B i: -9.91
Debt / Equity i: -5.09
Operating Margin: 13.34%
Net Margin: 4.76%
ROE i: -
ROIC: -

Financial Health

Score13 / 20
Debt / Equity: -5.09
Current Ratio: 1.89
Quick Ratio: 1.16
Status: Good
🧾

No insider activity

No recent insider transactions available.